A new government rule restricting cough syrup sales without a doctor’s prescription has triggered concern among chemists, patients, and lower-income families. In this ground report, local chemists explain how the decision could sharply reduce cough syrup sales and affect medicine access for people who often rely on pharmacy advice before visiting a doctor. Customers say doctor consultation fees, often starting around ₹400–₹500, make basic treatment expensive for many households. The discussion also raises questions about whether authorities should target specific unsafe formulations or companies instead of placing broad restrictions on all cough syrups. While the rule aims to improve safety after concerns linked to harmful syrups, its impact on everyday healthcare access could be significant. This video analyzes the practical challenges, public reaction, chemist concerns, and possible shift toward ayurvedic or homeopathic alternatives as prescription-only rules change how families treat cough and cold symptoms.